Bristol Myers Squibb (CELG-RI) Restructuring Costs (2009 - 2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Restructuring Costs of $33.0 million for Q1 2013, up 50.0% year-over-year from $22.0 million in Q1 2012, and down 67.96% quarter-over-quarter from $103.0 million in Q4 2012.
Bristol Myers Squibb (CELG-RI) Restructuring Costs (2009 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Restructuring Costs for 5 consecutive years, with $33.0 million the latest figure, recorded in Q1 2013.
- In Q1 2013, Restructuring Costs rose 50.0% year-over-year to $33.0 million; the TTM figure through Mar 2013 stood at $185.0 million (up 96.81% YoY), while the FY2012 annual figure was $174.0 million, up 50.0% from the prior year.
- Restructuring Costs fell to $33.0 million in Q1 2013 per CELG-RI's latest filing, from $103.0 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $103.0 million in Q4 2012 and bottomed at $8.0 million in Q3 2011.
- Historically, Restructuring Costs has averaged $33.1 million across 5 years, with a median of $24.0 million in 2010.
- Annual changes were most pronounced in 2010 — Restructuring Costs sank 72.22% — and 2012, when it jumped 329.17%.
- Bristol Myers Squibb's Restructuring Costs stood at $35.0 million in 2009, then soared by 80.0% to $63.0 million in 2010, then plunged by 61.9% to $24.0 million in 2011, then surged by 329.17% to $103.0 million in 2012, then plunged by 67.96% to $33.0 million in 2013.
- Business Quant data shows CELG-RI's Restructuring Costs at $33.0 million in Q1 2013, $103.0 million in Q4 2012, and $29.0 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 33.00 Mn |
| Dec 31, 2012 | 118.00 Mn |
| Sep 30, 2012 | 21.00 Mn |
| Jun 30, 2012 | 16.00 Mn |
| Mar 31, 2012 | 22.00 Mn |
| Dec 31, 2011 | 24.00 Mn |
| Sep 30, 2011 | 8.00 Mn |
| Jun 30, 2011 | 15.00 Mn |
| Mar 31, 2011 | 1.00 Mn |
| Dec 31, 2010 | 63.00 Mn |
| Sep 30, 2010 | 15.00 Mn |
| Jun 30, 2010 | 24.00 Mn |
| Mar 31, 2010 | 11.00 Mn |
| Dec 31, 2009 | -93.00 Mn |
| Sep 30, 2009 | 54.00 Mn |
| Jun 30, 2009 | 19.00 Mn |
| Mar 31, 2009 | 19.00 Mn |